{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:04:47Z","timestamp":1789873487883,"version":"4.0.1"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00467-023-06163-x","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T13:02:15Z","timestamp":1697202135000},"page":"1739-1758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hypertension in diabetes"],"prefix":"10.1007","volume":"39","author":[{"given":"Steve","family":"Balgobin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjukta","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Wei","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-6174","authenticated-orcid":false,"given":"Damien","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"6163_CR1","unstructured":"Sapra A, Bhandari P (2022) Diabetes\u00a0Mellitus.\u00a0In: StatPearls [Internet].\u00a0StatPearls Publishing, Treasure Island (FL)"},{"key":"6163_CR2","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"6163_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12902-015-0042-1","volume":"15","author":"M Zhu","year":"2015","unstructured":"Zhu M, Li J, Li Z et al (2015) Mortality rates and the causes of death related to diabetes mellitus in Shanghai Songjiang District: an 11-year retrospective analysis of death certificates. BMC Endocr Disord 15:45. https:\/\/doi.org\/10.1186\/s12902-015-0042-1","journal-title":"BMC Endocr Disord"},{"key":"6163_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","volume":"380","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Cushman WC (2012) Diabetes and hypertension: the bad companions. Lancet 380:601\u2013610. https:\/\/doi.org\/10.1016\/S0140-6736(12)60987-8","journal-title":"Lancet"},{"key":"6163_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B et al (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603\u2013615. https:\/\/doi.org\/10.1001\/jama.2014.18574","journal-title":"JAMA"},{"key":"6163_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2337\/diabetes.48.5.937","volume":"48","author":"M Laakso","year":"1999","unstructured":"Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937\u2013942. https:\/\/doi.org\/10.2337\/diabetes.48.5.937","journal-title":"Diabetes"},{"key":"6163_CR7","unstructured":"American Diabetes Association (2022) Statistics About Diabetes. https:\/\/diabetes.org\/about-us\/statistics\/about-diabetes. Accessed 26 May 2023"},{"key":"6163_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2021.11165","volume":"326","author":"JM Lawrence","year":"2021","unstructured":"Lawrence JM, Divers J, Isom S et al (2021) Trends in prevalence of Type 1 and Type 2 diabetes in children and adolescents in the US, 2001\u20132017. JAMA 326:717\u2013727. https:\/\/doi.org\/10.1001\/jama.2021.11165","journal-title":"JAMA"},{"key":"6163_CR9","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.2337\/dc20-S013","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association (2020) 13. Children and adolescents: Standards of medical care in Diabetes-2020. Diabetes Care 43:S163\u2013S182. https:\/\/doi.org\/10.2337\/dc20-S013","journal-title":"Diabetes Care"},{"key":"6163_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.24095\/hpcdp.39.11.03","volume":"39","author":"AG LeBlanc","year":"2019","unstructured":"LeBlanc AG, Gao YJ, McRae L, Pelletier C (2019) At-a-glance - Twenty years of diabetes surveillance using the Canadian Chronic Disease Surveillance System. Health Promot Chronic Dis Prev Can 39:306\u2013309","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"6163_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/01.hyp.19.5.403","volume":"19","author":"M Epstein","year":"1992","unstructured":"Epstein M, Sowers JR (1992) Diabetes mellitus and hypertension. Hypertension 19:403\u2013418. https:\/\/doi.org\/10.1161\/01.hyp.19.5.403","journal-title":"Hypertension"},{"key":"6163_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1081\/ceh-200031945","volume":"26","author":"L Landsberg","year":"2004","unstructured":"Landsberg L, Molitch M (2004) Diabetes and hypertension: pathogenesis, prevention and treatment. Clin Exp Hypertens 26:621\u2013628. https:\/\/doi.org\/10.1081\/ceh-200031945","journal-title":"Clin Exp Hypertens"},{"key":"6163_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/hr.2017.67","volume":"40","author":"Y Tatsumi","year":"2017","unstructured":"Tatsumi Y, Ohkubo T (2017) Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res 40:795\u2013806. https:\/\/doi.org\/10.1038\/hr.2017.67","journal-title":"Hypertens Res"},{"key":"6163_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-019-0859-4","volume":"18","author":"M Geva","year":"2019","unstructured":"Geva M, Shlomai G, Berkovich A et al (2019) The association between fasting plasma glucose and glycated hemoglobin in the prediabetes range and future development of hypertension. Cardiovasc Diabetol 18:53. https:\/\/doi.org\/10.1186\/s12933-019-0859-4","journal-title":"Cardiovasc Diabetol"},{"key":"6163_CR15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00125-006-0297-1","volume":"49","author":"IM Stratton","year":"2006","unstructured":"Stratton IM, Cull CA, Adler AI et al (2006) Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49:1761\u20131769. https:\/\/doi.org\/10.1007\/s00125-006-0297-1","journal-title":"Diabetologia"},{"key":"6163_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703\u2013713","journal-title":"BMJ"},{"key":"6163_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11892-012-0334-z","volume":"13","author":"MM George","year":"2013","unstructured":"George MM, Copeland KC (2013) Current treatment options for type 2 diabetes mellitus in youth: today\u2019s realities and lessons from the TODAY study. Curr Diab Rep 13:72\u201380. https:\/\/doi.org\/10.1007\/s11892-012-0334-z","journal-title":"Curr Diab Rep"},{"key":"6163_CR18","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981\u20132997. https:\/\/doi.org\/10.1001\/jama.288.23.2981","journal-title":"JAMA"},{"key":"6163_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/s0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351:1755\u20131762. https:\/\/doi.org\/10.1016\/s0140-6736(98)04311-6","journal-title":"HOT Study Group Lancet"},{"key":"6163_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jpeds.2010.02.021","volume":"157","author":"BL Rodriguez","year":"2010","unstructured":"Rodriguez BL, Dabelea D, Liese AD et al (2010) Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr 157:245-251.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2010.02.021","journal-title":"J Pediatr"},{"key":"6163_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/jc.2010-1642","volume":"96","author":"KC Copeland","year":"2011","unstructured":"Copeland KC, Zeitler P, Geffner M et al (2011) Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 96:159\u2013167. https:\/\/doi.org\/10.1210\/jc.2010-1642","journal-title":"J Clin Endocrinol Metab"},{"key":"6163_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/pedi.12281","volume":"17","author":"GJ Klingensmith","year":"2016","unstructured":"Klingensmith GJ, Connor CG, Ruedy KJ et al (2016) Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes 17:266\u2013273. https:\/\/doi.org\/10.1111\/pedi.12281","journal-title":"Pediatr Diabetes"},{"key":"6163_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/met.2008.0046","volume":"7","author":"EJ Mayer-Davis","year":"2009","unstructured":"Mayer-Davis EJ, Ma B, Lawson A et al (2009) Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. Metab Syndr Relat Disord 7:89\u201395. https:\/\/doi.org\/10.1089\/met.2008.0046","journal-title":"Metab Syndr Relat Disord"},{"issue":"668\u2013672","key":"6163_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jpeds.2009.05.025","volume":"155","author":"DB Petitti","year":"2009","unstructured":"Petitti DB, Klingensmith GJ, Bell RA et al (2009) Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr 155(668\u2013672):e1-3. https:\/\/doi.org\/10.1016\/j.jpeds.2009.05.025","journal-title":"J Pediatr"},{"key":"6163_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa2100165","volume":"385","author":"P Bjornstad","year":"2021","unstructured":"TODAY Study Group, Bjornstad P, Drews KL et al (2021) Long-term complications in youth-onset type 2 diabetes. N Engl J Med 385:416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa2100165","journal-title":"N Engl J Med"},{"key":"6163_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.amjhyper.2007.03.009","volume":"20","author":"T Seeman","year":"2007","unstructured":"Seeman T, Gil\u00edk J, Vondr\u00e1k K et al (2007) Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens 20:990\u2013996. https:\/\/doi.org\/10.1016\/j.amjhyper.2007.03.009","journal-title":"Am J Hypertens"},{"key":"6163_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","volume":"117","author":"Y-C Lin","year":"2018","unstructured":"Lin Y-C, Chang Y-H, Yang S-Y et al (2018) Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 117:662\u2013675. https:\/\/doi.org\/10.1016\/j.jfma.2018.02.007","journal-title":"J Formos Med Assoc"},{"key":"6163_CR28","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1210\/en.2003-0220","volume":"144","author":"T-J Hsieh","year":"2003","unstructured":"Hsieh T-J, Fustier P, Zhang S-L et al (2003) High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 144:4338\u20134349. https:\/\/doi.org\/10.1210\/en.2003-0220","journal-title":"Endocrinology"},{"key":"6163_CR29","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1172\/JCI33293","volume":"118","author":"I Toma","year":"2008","unstructured":"Toma I, Kang JJ, Sipos A et al (2008) Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest 118:2526\u20132534. https:\/\/doi.org\/10.1172\/JCI33293","journal-title":"J Clin Invest"},{"key":"6163_CR30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/ajh\/7.7.655","volume":"7","author":"RH Rao","year":"1994","unstructured":"Rao RH (1994) Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 7:655\u2013660. https:\/\/doi.org\/10.1093\/ajh\/7.7.655","journal-title":"Am J Hypertens"},{"key":"6163_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/0895-7061(96)00035-0","volume":"9","author":"SN Iyer","year":"1996","unstructured":"Iyer SN, Katovich MJ (1996) Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 9:662\u2013668. https:\/\/doi.org\/10.1016\/0895-7061(96)00035-0","journal-title":"Am J Hypertens"},{"key":"6163_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611\u2013616. https:\/\/doi.org\/10.1016\/s0140-6736(98)05012-0","journal-title":"Lancet"},{"key":"6163_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE et al (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995\u20131003. https:\/\/doi.org\/10.1016\/S0140-6736(02)08089-3","journal-title":"Lancet"},{"key":"6163_CR34","first-page":"853","volume":"3","author":"HAR Hadi","year":"2007","unstructured":"Hadi HAR, Suwaidi JA (2007) Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3:853\u2013876","journal-title":"Vasc Health Risk Manag"},{"key":"6163_CR35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/01.cir.103.9.1282","volume":"103","author":"JB Laursen","year":"2001","unstructured":"Laursen JB, Somers M, Kurz S et al (2001) Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103:1282\u20131288. https:\/\/doi.org\/10.1161\/01.cir.103.9.1282","journal-title":"Circulation"},{"key":"6163_CR36","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI21625","volume":"114","author":"S Furukawa","year":"2004","unstructured":"Furukawa S, Fujita T, Shimabukuro M et al (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752\u20131761. https:\/\/doi.org\/10.1172\/JCI21625","journal-title":"J Clin Invest"},{"key":"6163_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","volume":"25","author":"NR Madamanchi","year":"2005","unstructured":"Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29\u201338. https:\/\/doi.org\/10.1161\/01.ATV.0000150649.39934.13","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6163_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1042\/CS20060247","volume":"112","author":"C Savoia","year":"2007","unstructured":"Savoia C, Schiffrin EL (2007) Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 112:375\u2013384. https:\/\/doi.org\/10.1042\/CS20060247","journal-title":"Clin Sci (Lond)"},{"key":"6163_CR39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/01.ATV.0000069236.27911.68","volume":"23","author":"RM Touyz","year":"2003","unstructured":"Touyz RM, Yao G, Schiffrin EL (2003) c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23:981\u2013987. https:\/\/doi.org\/10.1161\/01.ATV.0000069236.27911.68","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6163_CR40","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1161\/01.RES.0000077044.60138.7C","volume":"92","author":"K Grote","year":"2003","unstructured":"Grote K, Flach I, Luchtefeld M et al (2003) Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 92:e80\u2013e86. https:\/\/doi.org\/10.1161\/01.RES.0000077044.60138.7C","journal-title":"Circ Res"},{"key":"6163_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1126\/science.7678183","volume":"259","author":"GS Hotamisligil","year":"1993","unstructured":"Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87\u201391. https:\/\/doi.org\/10.1126\/science.7678183","journal-title":"Science"},{"key":"6163_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/ATVBAHA.116.306256","volume":"37","author":"K Yahagi","year":"2017","unstructured":"Yahagi K, Kolodgie FD, Lutter C et al (2017) Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol 37:191\u2013204. https:\/\/doi.org\/10.1161\/ATVBAHA.116.306256","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6163_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1042\/CS20120198","volume":"124","author":"J Wada","year":"2013","unstructured":"Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124:139\u2013152. https:\/\/doi.org\/10.1042\/CS20120198","journal-title":"Clin Sci (Lond)"},{"key":"6163_CR44","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2337\/dc09-0763","volume":"32","author":"L Piemonti","year":"2009","unstructured":"Piemonti L, Calori G, Lattuada G et al (2009) Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 32:2105\u20132110. https:\/\/doi.org\/10.2337\/dc09-0763","journal-title":"Diabetes Care"},{"key":"6163_CR45","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1172\/JCI15318","volume":"110","author":"K Maedler","year":"2002","unstructured":"Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851\u2013860. https:\/\/doi.org\/10.1172\/JCI15318","journal-title":"J Clin Invest"},{"key":"6163_CR46","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2337\/db14-1018","volume":"64","author":"G Aharon-Hananel","year":"2015","unstructured":"Aharon-Hananel G, J\u00f6rns A, Lenzen S et al (2015) Antidiabetic effect of Interleukin-1\u03b2 antibody therapy through \u03b2-Cell protection in the Cohen diabetes-sensitive rat. Diabetes 64:1780\u20131785. https:\/\/doi.org\/10.2337\/db14-1018","journal-title":"Diabetes"},{"key":"6163_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712","volume":"27","author":"K Rehman","year":"2017","unstructured":"Rehman K, Akash MSH, Liaqat A et al (2017) Role of Interleukin-6 in development of insulin resistance and Type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 27:229\u2013236. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2017019712","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"6163_CR48","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/01.cir.0000034509.14906.ae","volume":"106","author":"K Esposito","year":"2002","unstructured":"Esposito K, Nappo F, Marfella R et al (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067\u20132072. https:\/\/doi.org\/10.1161\/01.cir.0000034509.14906.ae","journal-title":"Circulation"},{"key":"6163_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12986-018-0306-7","volume":"15","author":"J-H Chen","year":"2018","unstructured":"Chen J-H, Lin X, Bu C, Zhang X (2018) Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutr Metab 15:72. https:\/\/doi.org\/10.1186\/s12986-018-0306-7","journal-title":"Nutr Metab"},{"key":"6163_CR50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM (2018) Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol 34:575\u2013584. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"key":"6163_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tem.2013.08.002","volume":"25","author":"MB Manigrasso","year":"2014","unstructured":"Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM (2014) Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab TEM 25:15\u201322. https:\/\/doi.org\/10.1016\/j.tem.2013.08.002","journal-title":"Trends Endocrinol Metab TEM"},{"key":"6163_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.diabet.2015.01.006","volume":"41","author":"C Koulis","year":"2015","unstructured":"Koulis C, Watson AMD, Gray SP, Jandeleit-Dahm KA (2015) Linking RAGE and Nox in diabetic micro- and macrovascular complications. Diabetes Metab 41:272\u2013281. https:\/\/doi.org\/10.1016\/j.diabet.2015.01.006","journal-title":"Diabetes Metab"},{"key":"6163_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12265-012-9405-4","volume":"5","author":"KG Yamazaki","year":"2012","unstructured":"Yamazaki KG, Gonzalez E, Zambon AC (2012) Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast. J Cardiovasc Transl Res 5:805\u2013813. https:\/\/doi.org\/10.1007\/s12265-012-9405-4","journal-title":"J Cardiovasc Transl Res"},{"key":"6163_CR54","first-page":"639","volume":"52","author":"RM Touyz","year":"2000","unstructured":"Touyz RM, Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52:639\u2013672","journal-title":"Pharmacol Rev"},{"key":"6163_CR55","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/ATVBAHA.118.311229","volume":"38","author":"IAM Brown","year":"2018","unstructured":"Brown IAM, Diederich L, Good ME et al (2018) Vascular smooth muscle remodeling in conductive and resistance arteries in hypertension. Arterioscler Thromb Vasc Biol 38:1969\u20131985. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311229","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6163_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000479560","volume":"5","author":"MF Elias","year":"2018","unstructured":"Elias MF, Crichton GE, Dearborn PJ et al (2018) Associations between Type 2 diabetes mellitus and arterial stiffness: a prospective analysis based on the Maine-Syracuse study. Pulse (Basel) 5:88\u201398. https:\/\/doi.org\/10.1159\/000479560","journal-title":"Pulse (Basel)"},{"key":"6163_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fgene.2017.00187","volume":"8","author":"LM Senatus","year":"2017","unstructured":"Senatus LM, Schmidt AM (2017) The AGE-RAGE Axis: implications for age-associated arterial diseases. Front Genet 8:187. https:\/\/doi.org\/10.3389\/fgene.2017.00187","journal-title":"Front Genet"},{"key":"6163_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0037-1598183","volume":"26","author":"K Prasad","year":"2017","unstructured":"Prasad K, Mishra M (2017) Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension? Int J Angiol 26:1\u201311. https:\/\/doi.org\/10.1055\/s-0037-1598183","journal-title":"Int J Angiol"},{"key":"6163_CR59","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/01.ATV.0000131783.74034.97","volume":"24","author":"AP Burke","year":"2004","unstructured":"Burke AP, Kolodgie FD, Zieske A et al (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24:1266\u20131271. https:\/\/doi.org\/10.1161\/01.ATV.0000131783.74034.97","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6163_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/01.hyp.11.1.3","volume":"11","author":"M Esler","year":"1988","unstructured":"Esler M, Jennings G, Korner P et al (1988) Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11:3\u201320. https:\/\/doi.org\/10.1161\/01.hyp.11.1.3","journal-title":"Hypertension"},{"key":"6163_CR61","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1152\/physrev.1990.70.4.963","volume":"70","author":"M Esler","year":"1990","unstructured":"Esler M, Jennings G, Lambert G et al (1990) Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 70:963\u2013985. https:\/\/doi.org\/10.1152\/physrev.1990.70.4.963","journal-title":"Physiol Rev"},{"key":"6163_CR62","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00004872-199917060-00001","volume":"17","author":"G Grassi","year":"1999","unstructured":"Grassi G, Esler M (1999) How to assess sympathetic activity in humans. J Hypertens 17:719\u2013734. https:\/\/doi.org\/10.1097\/00004872-199917060-00001","journal-title":"J Hypertens"},{"key":"6163_CR63","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI115260","volume":"87","author":"EA Anderson","year":"1991","unstructured":"Anderson EA, Hoffman RP, Balon TW et al (1991) Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246\u20132252","journal-title":"J Clin Invest"},{"key":"6163_CR64","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2337\/diabetes.51.1.42","volume":"51","author":"MA Vincent","year":"2002","unstructured":"Vincent MA, Dawson D, Clark ADH et al (2002) Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 51:42\u201348. https:\/\/doi.org\/10.2337\/diabetes.51.1.42","journal-title":"Diabetes"},{"key":"6163_CR65","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1152\/ajpendo.00021.2003","volume":"285","author":"MA Vincent","year":"2003","unstructured":"Vincent MA, Barrett EJ, Lindner JR et al (2003) Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 285:E123\u2013E129. https:\/\/doi.org\/10.1152\/ajpendo.00021.2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6163_CR66","doi-asserted-by":"publisher","first-page":"H813","DOI":"10.1152\/ajpheart.00092.2005","volume":"289","author":"MA Potenza","year":"2005","unstructured":"Potenza MA, Marasciulo FL, Chieppa DM et al (2005) Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 289:H813-822. https:\/\/doi.org\/10.1152\/ajpheart.00092.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"6163_CR67","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1172\/JCI114644","volume":"85","author":"M Laakso","year":"1990","unstructured":"Laakso M, Edelman SV, Brechtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844\u20131852","journal-title":"J Clin Invest"},{"key":"6163_CR68","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MCO.0b013e328042ba90","volume":"10","author":"J Delarue","year":"2007","unstructured":"Delarue J, Magnan C (2007) Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 10:142\u2013148. https:\/\/doi.org\/10.1097\/MCO.0b013e328042ba90","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"6163_CR69","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/01.HYP.23.6.1006","volume":"23","author":"K Jamerson","year":"1994","unstructured":"Jamerson K, Smith S, Amerena J et al (1994) Vasoconstriction With Norepinephrine Causes Less Forearm Insulin Resistance Than a Reflex Sympathetic Vasoconstriction. Hypertension 23:1006\u20131011","journal-title":"Hypertension"},{"key":"6163_CR70","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.cir.103.4.513","volume":"103","author":"M Emdin","year":"2001","unstructured":"Emdin M, Gastaldelli A, Muscelli E et al (2001) Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 103:513\u2013519. https:\/\/doi.org\/10.1161\/01.cir.103.4.513","journal-title":"Circulation"},{"key":"6163_CR71","doi-asserted-by":"publisher","first-page":"R633","DOI":"10.1152\/ajpregu.00258.2005","volume":"289","author":"GF DiBona","year":"2005","unstructured":"DiBona GF (2005) Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289:R633\u2013R641. https:\/\/doi.org\/10.1152\/ajpregu.00258.2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"6163_CR72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/01.HYP.0000242642.42177.49","volume":"48","author":"M Esler","year":"2006","unstructured":"Esler M, Straznicky N, Eikelis N et al (2006) Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48:787\u2013796. https:\/\/doi.org\/10.1161\/01.HYP.0000242642.42177.49","journal-title":"Hypertension"},{"key":"6163_CR73","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","volume":"123","author":"F Mahfoud","year":"2011","unstructured":"Mahfoud F, Schlaich M, Kindermann I et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123:1940\u20131946. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.991869","journal-title":"Circulation"},{"key":"6163_CR74","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1161\/CIR.0000000000000601","volume":"138","author":"DM Reboussin","year":"2018","unstructured":"Reboussin DM, Allen NB, Griswold ME et al (2018) Systematic Review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 138:e595\u2013e616. https:\/\/doi.org\/10.1161\/CIR.0000000000000601","journal-title":"Circulation"},{"key":"6163_CR75","doi-asserted-by":"publisher","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904. https:\/\/doi.org\/10.1542\/peds.2017-1904","journal-title":"Pediatrics"},{"key":"6163_CR76","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507\u2013520. https:\/\/doi.org\/10.1001\/jama.2013.284427","journal-title":"JAMA"},{"key":"6163_CR77","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"6163_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3399\/bjgp20X708053","volume":"70","author":"NR Jones","year":"2020","unstructured":"Jones NR, McCormack T, Constanti M, McManus RJ (2020) Diagnosis and management of hypertension in adults: NICE guideline update 2019. Br J Gen Pract 70:90\u201391. https:\/\/doi.org\/10.3399\/bjgp20X708053","journal-title":"Br J Gen Pract"},{"key":"6163_CR79","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1684\/stv.2013.0798","volume":"25","author":"J Blacher","year":"2013","unstructured":"Blacher J, Halimi J-M, Hanon O et al (2013) Management of arterial hypertension in adults: 2013 guidelines of the French Society of Arterial Hypertension. Sang Thromb Vaiss 25:297\u2013305. https:\/\/doi.org\/10.1684\/stv.2013.0798","journal-title":"Sang Thromb Vaiss"},{"key":"6163_CR80","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","volume":"16","author":"Joint Committee for Guideline Revision","year":"2019","unstructured":"Joint Committee for Guideline Revision (2019) 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol 16:182\u2013241. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2019.03.014","journal-title":"J Geriatr Cardiol"},{"key":"6163_CR81","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5694\/mja16.00526","volume":"205","author":"GM Gabb","year":"2016","unstructured":"Gabb GM, Mangoni AA, Anderson CS et al (2016) Guideline for the diagnosis and management of hypertension in adults \u2014 2016. Med J Aust 205:85\u201389","journal-title":"Med J Aust"},{"key":"6163_CR82","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","volume":"36","author":"DM Rabi","year":"2020","unstructured":"Rabi DM, McBrien KA, Sapir-Pichhadze R et al (2020) Hypertension Canada\u2019s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 36:596\u2013624. https:\/\/doi.org\/10.1016\/j.cjca.2020.02.086","journal-title":"Can J Cardiol"},{"key":"6163_CR83","unstructured":"International Diabetes Federation (2017) IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care. https:\/\/idf.org\/media\/uploads\/2023\/05\/attachments-63.pdf.\u00a0Accessed 30 June 2023"},{"key":"6163_CR84","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F et al (2020) 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 75:1334\u20131357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026","journal-title":"Hypertension"},{"key":"6163_CR85","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/HJH.0000000000001039","volume":"34","author":"E Lurbe","year":"2016","unstructured":"Lurbe E, Agabiti-Rosei E, Cruickshank JK et al (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887\u20131920. https:\/\/doi.org\/10.1097\/HJH.0000000000001039","journal-title":"J Hypertens"},{"key":"6163_CR86","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cjca.2017.03.007","volume":"33","author":"JM Dionne","year":"2017","unstructured":"Dionne JM, Harris KC, Benoit G et al (2017) Hypertension Canada\u2019s 2017 guidelines for the diagnosis, assessment, prevention, and treatment of pediatric hypertension. Can J Cardiol 33:577\u2013585. https:\/\/doi.org\/10.1016\/j.cjca.2017.03.007","journal-title":"Can J Cardiol"},{"key":"6163_CR87","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837\u2013853","journal-title":"Lancet"},{"key":"6163_CR88","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575\u20131585. https:\/\/doi.org\/10.1056\/NEJMoa1001286","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"6163_CR89","first-page":"B54","volume":"23","author":"RO Estacio","year":"2000","unstructured":"Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54\u2013B64","journal-title":"Diabetes Care"},{"key":"6163_CR90","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","volume":"61","author":"RW Schrier","year":"2002","unstructured":"Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086\u20131097. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00213.x","journal-title":"Kidney Int"},{"key":"6163_CR91","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82\u2013C97. https:\/\/doi.org\/10.1152\/ajpcell.00287.2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"6163_CR92","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3949\/ccjm.86a.19016","volume":"86","author":"H Rincon-Choles","year":"2019","unstructured":"Rincon-Choles H (2019) ACE inhibitor and ARB therapy: Practical recommendations. Cleve Clin J Med 86:608\u2013611. https:\/\/doi.org\/10.3949\/ccjm.86a.19016","journal-title":"Cleve Clin J Med"},{"key":"6163_CR93","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/heartjnl-2016-310705","volume":"103","author":"L Potier","year":"2017","unstructured":"Potier L, Roussel R, Elbez Y et al (2017) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart Br Card Soc 103:1339\u20131346. https:\/\/doi.org\/10.1136\/heartjnl-2016-310705","journal-title":"Heart Br Card Soc"},{"key":"6163_CR94","unstructured":"Mann JFE, Hilgers K (2021) Renal effects of ACE inhibitors in hypertension - UpToDate. https:\/\/www-uptodate-com.myaccess.library.utoronto.ca\/contents\/renal-effects-of-ace-inhibitors-in-hypertension?search=renal%20effects%20of%20ace&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed 23 Oct 2021"},{"key":"6163_CR95","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1177\/1060028018779082","volume":"52","author":"A Helmer","year":"2018","unstructured":"Helmer A, Slater N, Smithgall S (2018) A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother 52:1143\u20131151. https:\/\/doi.org\/10.1177\/1060028018779082","journal-title":"Ann Pharmacother"},{"key":"6163_CR96","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","volume":"369","author":"RE Schmieder","year":"2007","unstructured":"Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369:1208\u20131219. https:\/\/doi.org\/10.1016\/S0140-6736(07)60242-6","journal-title":"Lancet"},{"key":"6163_CR97","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1681\/ASN.2005121337","volume":"17","author":"GFM Strippoli","year":"2006","unstructured":"Strippoli GFM, Craig MC, Schena FP, Craig JC (2006) Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 17:S153-155. https:\/\/doi.org\/10.1681\/ASN.2005121337","journal-title":"J Am Soc Nephrol"},{"key":"6163_CR98","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1681\/ASN.2004080634","volume":"16","author":"GFM Strippoli","year":"2005","unstructured":"Strippoli GFM, Craig M, Schena FP, Craig JC (2005) Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 16:3081\u20133091. https:\/\/doi.org\/10.1681\/ASN.2004080634","journal-title":"J Am Soc Nephrol"},{"key":"6163_CR99","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782\u2013788. https:\/\/doi.org\/10.1016\/s0140-6736(03)14286-9","journal-title":"Lancet"},{"key":"6163_CR100","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3317\/jraas.2000.002","volume":"1","author":"P Sleight","year":"2000","unstructured":"Sleight P (2000) The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin-Angiotensin-Aldosterone Syst 1:18\u201320","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"6163_CR101","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41440-019-0234-6","volume":"42","author":"A Kunimura","year":"2019","unstructured":"Kunimura A, Himuro N, Fujiyoshi A et al (2019) The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Hypertens Res 42:669\u2013680. https:\/\/doi.org\/10.1038\/s41440-019-0234-6","journal-title":"Hypertens Res"},{"key":"6163_CR102","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41371-018-0066-x","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Chen Y, Li L et al (2018) First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 32:494\u2013506. https:\/\/doi.org\/10.1038\/s41371-018-0066-x","journal-title":"J Hum Hypertens"},{"key":"6163_CR103","doi-asserted-by":"publisher","first-page":"i438","DOI":"10.1136\/bmj.i438","volume":"352","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Messerli FH (2016) Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 352:i438. https:\/\/doi.org\/10.1136\/bmj.i438","journal-title":"BMJ"},{"key":"6163_CR104","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40618-020-01179-8","volume":"43","author":"X Liu","year":"2020","unstructured":"Liu X, Ma L, Li Z (2020) Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. J Endocrinol Invest 43:959\u2013972. https:\/\/doi.org\/10.1007\/s40618-020-01179-8","journal-title":"J Endocrinol Invest"},{"key":"6163_CR105","doi-asserted-by":"publisher","first-page":"147032031665648","DOI":"10.1177\/1470320316656481","volume":"17","author":"J Shen","year":"2016","unstructured":"Shen J, Huang Y-M, Song X-N et al (2016) Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin-Angiotensin-Aldosterone Syst 17:1470320316656481. https:\/\/doi.org\/10.1177\/1470320316656481","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"6163_CR106","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/ajh.2008.206","volume":"21","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN (2008) Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens 21:922\u2013929. https:\/\/doi.org\/10.1038\/ajh.2008.206","journal-title":"Am J Hypertens"},{"key":"6163_CR107","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","volume":"390","author":"A Levin","year":"2017","unstructured":"Levin A, Tonelli M, Bonventre J et al (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390:1888\u20131917. https:\/\/doi.org\/10.1016\/S0140-6736(17)30788-2","journal-title":"Lancet"},{"key":"6163_CR108","doi-asserted-by":"publisher","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","volume":"300","author":"V Vallon","year":"2011","unstructured":"Vallon V (2011) The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300:R1009\u2013R1022. https:\/\/doi.org\/10.1152\/ajpregu.00809.2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"6163_CR109","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.ajkd.2018.03.022","volume":"72","author":"RZ Alicic","year":"2018","unstructured":"Alicic RZ, Johnson EJ, Tuttle KR (2018) SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis 72:267\u2013277. https:\/\/doi.org\/10.1053\/j.ajkd.2018.03.022","journal-title":"Am J Kidney Dis"},{"key":"6163_CR110","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2337\/ds20-0038","volume":"34","author":"R Teng","year":"2021","unstructured":"Teng R, Kurian M, Close KL et al (2021) Comparison of protocols to reduce diabetic ketoacidosis in patients with Type 1 diabetes prescribed a sodium-glucose cotransporter 2 inhibitor. Diabetes Spectr 34:42\u201351. https:\/\/doi.org\/10.2337\/ds20-0038","journal-title":"Diabetes Spectr"},{"key":"6163_CR111","unstructured":"US Food and Drug Administration (2021) FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease.\u00a0Accessed 30 June 2023"},{"key":"6163_CR112","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","volume":"10","author":"WV Tamborlane","year":"2022","unstructured":"Tamborlane WV, Laffel LM, Shehadeh N et al (2022) Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol 10:341\u2013350. https:\/\/doi.org\/10.1016\/S2213-8587(22)00052-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6163_CR113","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"6163_CR114","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"6163_CR115","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"6163_CR116","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jch.12425","volume":"16","author":"MR Weir","year":"2014","unstructured":"Weir MR, Januszewicz A, Gilbert RE et al (2014) Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens 16:875\u2013882. https:\/\/doi.org\/10.1111\/jch.12425","journal-title":"J Clin Hypertens"},{"key":"6163_CR117","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP et al (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17:1180\u20131193. https:\/\/doi.org\/10.1111\/dom.12572","journal-title":"Diabetes Obes Metab"},{"key":"6163_CR118","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/nep.13979","volume":"27","author":"B Jiang","year":"2022","unstructured":"Jiang B, Cheng Z, Liu F et al (2022) Renoprotection with sodium-glucose cotransporter-2 inhibitors in children: knowns and unknowns. Nephrology 27:126\u2013132. https:\/\/doi.org\/10.1111\/nep.13979","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"6163_CR119","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","volume":"124","author":"JB McGill","year":"2019","unstructured":"McGill JB, Subramanian S (2019) Safety of Sodium-Glucose Co-Transporter 2 inhibitors. Am J Cardiol 124(Suppl 1):S45\u2013S52. https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.029","journal-title":"Am J Cardiol"},{"key":"6163_CR120","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S (2016) Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev 5:488\u2013501. https:\/\/doi.org\/10.1002\/cpdd.263","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6163_CR121","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E et al (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone\u2019s Antifibrotic activity. Hypertension 71:599\u2013608. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10360","journal-title":"Hypertension"},{"key":"6163_CR122","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"6163_CR123","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and Type 2 diabetes. N Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"6163_CR124","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","volume":"25","author":"TA Mavrakanas","year":"2014","unstructured":"Mavrakanas TA, Gariani K, Martin P-Y (2014) Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med 25:173\u2013176. https:\/\/doi.org\/10.1016\/j.ejim.2013.11.007","journal-title":"Eur J Intern Med"},{"key":"6163_CR125","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","volume":"11","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in Type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol 11:178. https:\/\/doi.org\/10.3389\/fendo.2020.00178","journal-title":"Front Endocrinol"},{"key":"6163_CR126","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2337\/dc14-1958","volume":"38","author":"JA Lovshin","year":"2015","unstructured":"Lovshin JA, Barnie A, DeAlmeida A et al (2015) Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38:132\u2013139. https:\/\/doi.org\/10.2337\/dc14-1958","journal-title":"Diabetes Care"},{"key":"6163_CR127","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM et al (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13:605\u2013628. https:\/\/doi.org\/10.1038\/nrneph.2017.123","journal-title":"Nat Rev Nephrol"},{"key":"6163_CR128","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","volume":"381","author":"WV Tamborlane","year":"2019","unstructured":"Tamborlane WV, Barrientos-P\u00e9rez M, Fainberg U et al (2019) Liraglutide in children and adolescents with Type 2 diabetes. N Engl J Med 381:637\u2013646. https:\/\/doi.org\/10.1056\/NEJMoa1903822","journal-title":"N Engl J Med"},{"key":"6163_CR129","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"6163_CR130","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S et al (2015) Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 110:26\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2015.07.015","journal-title":"Diabetes Res Clin Pract"},{"key":"6163_CR131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(09)60659-0","journal-title":"Lancet"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-06163-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T13:06:15Z","timestamp":1713445575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-06163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6163"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-06163-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors contributed to the design and conception of this review article. SB (first author) drafted the initial work which was critically revised by the other authors. All authors approved the final version and agree to be accountable for the integrity and accuracy of the work. The authors have nothing to disclose and no conflicts of interests with respect to any of the medications discussed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}